Document:

EX-10.6

 Exhibit 10.6 
  

			
	

		1555 Adams Drive
			Menlo Park, CA 94025
			T. 650.641.2100
			F. 650.641.2120

 January 30, 2015 
 VIA HAND
DELIVERY 
 Amy C. Wolbeck 
 Intersect ENT, Inc. 

1555 Adams Drive 
 Menlo Park, CA 94025 

 

	Re:	Employment Terms 

 Dear Amy: 

On January 21, 2015, the Compensation Committee of the Board of Directors of Intersect ENT, Inc. (the “Company”)
approved an amendment to the terms of your compensation in connection a change of control of the Company or termination of your employment. This letter sets forth those terms and supersedes the terms set forth in your employment offer letter dated
November 24, 2008, as amended (the “Offer Letter”). Effective as of January 21, 2015, the changes to your benefits are as follows: 

1) Severance Upon Termination Other Than in Connection with Change in Control: 

If, other than in connection with or within twelve (12) months after a Change of Control Transaction (as defined below), your employment is either
(i) terminated by the Company or a successor entity without Cause (defined below), or (ii) terminated by you due to your resignation for Good Reason (defined below), provided that such termination constitutes a “separation from
service” (as defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative definition thereunder, a “Separation from Service”), you shall be entitled to (i) payment of six
(6) months of your base salary, less all applicable withholdings and deductions, paid over such 6-month period immediately following the Separation from Service, on the schedule described below, and (ii) six (6) months COBRA
reimbursement. 
 2) Severance Upon Termination or in Connection with Change in Control: 

Upon the occurrence of a Change of Control Transaction, the vesting of all outstanding stock options held by you shall be accelerated such that 50% unvested
shares subject to your outstanding options shall be fully vested. 

 Amy C. Wolbeck 

 Page
 2
 
  

 If, in connection with or within twelve (12) months after a Change of Control Transaction, a Separation
from Service occurs, you shall be entitled to (i) payment of six (6) months of your base salary, less all applicable withholdings and deductions, paid over such 6-month period immediately following the Separation from Service, on the
schedule described below, (ii) a lump sum payment equal to your annual target bonus prorated for the number of days of the then current bonus period worked prior to your Separation from Service, (iii) six (6) months COBRA
reimbursement and (iv) vesting of all outstanding stock options held by you such that all unvested shares subject to your outstanding options shall be fully vested, but only if the event constituting Good Reason upon which your resignation is
based occurs in connection with or subsequent to and as a result of such Change of Control Transaction. 
 The severance benefits set forth in
sections 1 and 2 above are conditional upon (a) your continuing to comply with your obligations under your Proprietary Information and Inventions Agreement during the period of time in which you are receiving the Severance Benefits; and
(b) your delivering to the Company an effective, general release of claims in favor of the Company in a form acceptable to the Company within 60 days following your Separation from Service. The salary continuation set forth above will be paid
in equal installments on the Company’s regular payroll schedule and will be subject to applicable tax withholdings over the period outlined above following the date of your Separation from Service; provided, however, that no payments
will be made prior to the 60th day following your Separation from Service. On the 60th day following your Separation from Service, the Company will pay you in a lump sum the Salary Continuation and the pro-rated target bonus payment that you would
have received on or prior to such date under the original schedule but for the delay while waiting for the 60th day in compliance with Section 409A of the Internal Revenue Code of 1986, as
amended (“Code Section 409A”) and the effectiveness of the release, with the balance of the salary continuation being paid as originally scheduled. 

3) Definitions: 
 (a)
A “Change of Control Transaction” shall be deemed to be occasioned by, or to include, (i) the liquidation, dissolution or winding up of the Company; (ii) the acquisition of the Company by another entity by means
of any transaction or series of related transactions (including, without limitation, any stock acquisition, reorganization, merger or consolidation but excluding any sale of stock for capital raising purposes) other than by means of a transaction or
series of transactions in which the holders of the voting securities of the Company outstanding immediately prior to such transaction continue to retain (either by such voting securities remaining outstanding or by such voting securities being
converted into voting securities of the surviving entity), as a result of shares in the Company held by such holders prior to such transaction, at least 50% of the total voting power represented by the voting securities of the Company or such
surviving entity outstanding immediately after such transaction or series of transactions, and (iii) a sale, exclusive license or other conveyance of all or substantially all of the assets of the Company, by means of a transaction or series of
transactions. 
 (b) For the purposes of the Offer Letter, “Cause” shall mean any of the following conduct by
you: (i) embezzlement, misappropriation of corporate funds, or other material acts of dishonesty; (ii) commission or conviction of any felony, or of any misdemeanor involving moral turpitude, or entry of a plea of guilty or nolo contendere
to any felony or misdemeanor; (iii) engagement in any activity that you know or should know could materially harm the business or 

 Amy C. Wolbeck 

 Page
 3
 
  

 
reputation of the Company; (iv) material failure to adhere to the Company’s corporate codes, policies or procedures as in effect from time to time; (v) material violation of any
statutory, contractual, or common law duty or obligation to the Company, including, without limitation, the duty of loyalty; (vi) material breach of the Confidentiality Agreement; (vii) repeated failure, in the reasonable judgment of the
Board, to substantially perform your assigned duties or responsibilities after written notice from the Board describing the failure(s) in reasonable detail and your failure to cure such failure(s) within thirty (30) days of receiving such
written notice; or material breach of the Proprietary Information and Inventions Agreement executed by you. 
 (c)
For the purposes of the Offer Letter, “Good Reason” shall mean any of the following which occurs without your written consent: (i) a relocation of the office where you are required to work to a location
more than thirty-five (35) miles from the office where you previously were required to work; (ii) a material decrease in your base salary (except for salary decreases generally applicable to the Company’s other executive employees);
or (iii) a material reduction in the scope of your duties or responsibilities, provided, however, that to resign for Good Reason, you must (1) provide written notice to
the Company’s Chief Executive Officer within 30 days after the first occurrence of the event giving rise to Good Reason setting forth the basis for your resignation, (2) allow the Company at least 30 days from receipt of such written
notice to cure such event, and (3) if such event is not reasonably cured within such period, your resignation from all positions you then hold with the Company is effective not later than 90 days after the expiration of the cure period.

 Except as modified herein, all other terms of your employment shall remain in full force and effect. 

 Amy C. Wolbeck 

 Page
 4
 
  

 Please sign below if these terms are acceptable to you, and return the fully signed letter to me. 

Understood and Agreed: 
  

					
	 /s/ Amy C. Wolbeck
				 /s/ Lisa D. Earnhardt

	Amy C. Wolbeck				Lisa D. Earnhardt
	Vice President, Regulatory Affairs and Quality				President and Chief Executive Officer
	Intersect ENT, Inc.				Intersect ENT, Inc.
			
	 Jan 30, 2015
				 Feb 9, 2015

	 Date
				DateEX-10.7

 Exhibit 10.7 
  

 
 January 21, 2015 

Mr. Charles S. McKhann 
 Via Email 

 

	Re:	Employment Terms 

 Dear Chas: 

Intersect ENT, Inc. (the “Company”) is pleased to offer you the position of Chief Commercial Officer on the following terms. 

You will be responsible for all aspects of the Company’s Global Commercial Operations, including sales, marketing, business development,
reimbursement/healthcare economics, and customer support. You will report directly to me, as the Company’s CEO, and you will be based at our offices located in Menlo Park, California. Of course, the Company may change your position, duties, and
work location from time to time in its discretion. 
 Your base salary will be $320,000 per year, less payroll deductions and all required withholdings. You
will be paid every other Friday and you will be eligible for the Company’s standard benefits, including: health, dental, and vision insurance, paid time off, and holidays. Details about all our benefit plans are available for your review. In
addition, you will also be eligible for an annual bonus of up to 40% of your base salary or $128,000, less deductions and required withholdings. Your annual bonus will be determined in the sole discretion of the Company based upon an evaluation of
both your performance and the Company’s performance. To be eligible for any such bonus, you must remain employed through the time when bonuses are paid in the first quarter after the end of the fiscal year to which the bonus applies. The
Company may change compensation and benefits from time to time in its discretion. As an exempt salaried employee, you will not be eligible for overtime pay. Subject to your commencing employment on February 2, 2015 the Company will pay you a
lump sum cash sign-on bonus (“Sign-on Bonus”) of $30,000.00, subject to applicable tax withholdings. The Sign-On Bonus will be paid not later than the first full payroll cycle after your start date. This bonus is being paid to
you as an advance. You must be employed for one year in order to earn the bonus. Therefore, if your employment with the Company ends for any reason within the first twelve (12) months after your start date, you will be required to
repay a pro-rata amount of the after tax value of the signing bonus, based on the number of days you were not actually employed during such period. 

 Chas McKhann 

January 21, 2015 
  Page
 2
 
  

 The Company will reimburse you for reasonable expenses (“Commuting Expenses”) incurred by you in
connection with your commute to our office in Menlo Park, California. To the extent such Commuting Expenses are deemed income; the Company will provide you with an annual gross-up payment of up to 68% at the applicable rate for any taxes incurred by
you in connection with the payment of your Commuting Expenses. 
 Subject to and following approval by the Company’s Board of Directors (the
“Board”), the Company shall grant you an option to purchase 100,000 shares of the Company’s common stock at the fair market value as determined by the Board as of the date of grant (the “Option”). The Option will be subject
to the terms and conditions of the Company’s Equity Incentive Plan (the “Plan”) and your grant agreement. Your grant agreement will provide for vesting of the Option as determined by the Board. 

Upon the occurrence of a Change in Control (as defined below), 100% of the then unvested shares subject to the Option shall be fully vested. Notwithstanding
the foregoing, as a pre-condition of the accelerated vesting referenced in the immediately preceding sentence, you will be required to timely sign, date and return to the Company (or its successor), and to not subsequently revoke, a general release
of all known and unknown claims in the form provided to you by the Company. 
 In addition, you shall receive the Severance Benefits (as defined below) if
your employment is either (i) terminated by the Company or a successor entity without Cause (defined below), or (ii) terminated by you due to your resignation for Good Reason (defined below), provided that such termination constitutes a
“separation from service” (as defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative definition thereunder, a “Separation from Service”). 

For purposes of the above paragraph, the following definitions shall apply: 

(1) Change in Control. For the purposes of the Offer Letter, “Change in Control” shall mean the following: (A) any
consolidation or merger of the Company with or into any other corporation or other entity or person, or any other corporate reorganization, other than any such consolidation, merger or reorganization in which the stockholders of the Company
immediately prior to such consolidation, merger or reorganization, continue to hold a majority of the voting power of the surviving entity (or, if the surviving entity is a wholly owned subsidiary, its parent) immediately after such consolidation,
merger or reorganization; (B) any transaction or series of related transactions to which the Company is a party in which in excess of fifty percent (50%) of the Company’s voting power is transferred; provided that the foregoing shall
not include any transaction or series of transactions principally for bona fide equity financing purposes in which cash is received by the Company or indebtedness of the Company is cancelled or converted or a combination thereof; or (C) a sale,
lease, exclusive license or other disposition of all or substantially all of the assets of the Company. 
 (2) Cause. For the
purposes of the Offer Letter, “Cause” shall mean any of the following conduct by you: (i) embezzlement, misappropriation of corporate funds, or other material acts of dishonesty; (ii) commission or conviction of any felony, or of
any misdemeanor  

 Chas McKhann 

January 21, 2015 
  Page
 3
 
  

 
involving moral turpitude, or entry of a plea of guilty or nolo contendere to any felony or misdemeanor; (iii) engagement in any activity that you know or should know could materially harm
the business or reputation of the Company; (iv) material failure to adhere to the Company’s corporate codes, policies or procedures as in effect from time to time; (v) material violation of any statutory, contractual, or common law
duty or obligation to the Company, including, without limitation, the duty of loyalty; (vi) material breach of the Confidentiality Agreement; (vii) repeated failure, in the reasonable judgment of the Board, to substantially perform your
assigned duties or responsibilities after written notice from the Board describing the failure(s) in reasonable detail and your failure to cure such failure(s) within thirty (30) days of receiving such written notice; or material breach of the
Proprietary Information and Inventions Agreement executed by you. 
 (3) Good Reason. For the purposes of the Offer Letter, “Good
Reason” shall mean any of the following which occurs without your written consent: (i) a relocation of the office where you are required to work to a location more than thirty-five (35) miles from the office where you previously were
required to work; (ii) a material decrease in your base salary (except for salary decreases generally applicable to the Company’s other executive employees); or (iii) a material reduction in the scope of your duties or
responsibilities, provided, however, that to resign for Good Reason, you must (1) provide written notice to the Company’s chief Executive Officer within 30 days after the first occurrence of the event giving rise to Good Reason setting
forth the basis for your resignation, (2) allow the Company at least 30 days from receipt of such written notice to cure such event, and (3) if such event is not reasonably cured within such period, your resignation from all positions you
then hold with the Company is effective not later than 90 days after the expiration of the cure period. 
 (4) Severance Benefits.
For the purposes of the Offer Letter, “Severance Benefits” shall mean (i) payment of twelve (12) months of your base salary, less all applicable withholdings and deductions, paid over such 12-month period immediately
following the Separation from Service, on the schedule described below (the “Salary Continuation”); (ii) a lump sum payment equal to your annual target bonus prorated for the number of days of the then current bonus period worked
prior to your Separation from Service; (iii) vesting of all outstanding stock options held by you such that all unvested shares subject to your outstanding options shall be fully vested; and (iv) twelve (12) months COBRA
reimbursement. Such Severance Benefits are conditional upon (a) your continuing to comply with your obligations under your Proprietary Information and Inventions Agreement during the period of time in which you are receiving the Severance
Benefits; and (b) your delivering to the Company an effective, general release of claims in favor of the Company in a form acceptable to the Company within 60 days following your Separation from Service. The Salary Continuation will be paid in
equal installments on the Company’s regular payroll schedule and will be subject to applicable tax withholdings over the period outlined above following the date of your Separation from Service; provided, however, that no payments will be made
prior to the 60th day following your Separation from Service. On the 60th day following your Separation from Service, the Company will pay you in a lump sum the Salary Continuation and the pro-rated target bonus payment that you would have received
on or prior to such date under the original schedule but for the delay while waiting for the 60th day in compliance with Section 409A of the Internal Revenue Code of 1986, as amended (“Code Section 409A”) and the effectiveness of
the release, with the balance of the Salary Continuation being paid as originally scheduled. 

 Chas McKhann 

January 21, 2015 
  Page
 4
 
  

 As a condition of your employment, you will be required to abide by the Company’s policies and
procedures. You also agree to read, sign and comply with the Company’s Employee Confidential Information and Inventions Agreement (“Confidential Information Agreement”). 

In your work for the Company, you will be expected not to make unauthorized use or disclosure of any confidential information or materials, including trade
secrets, of any former employer or other third party to whom you have an obligation of confidentiality. Rather, you will be expected to use only that information generally known and used by persons with training and experience comparable to your
own, which is common knowledge in the industry or otherwise legally in the public domain, or which is otherwise provided or developed by the Company. By accepting employment with the Company, you are representing to us that you will be able to
perform your duties within the guidelines described in this paragraph. You represent further that you have disclosed to the Company any contract you have signed that may restrict your activities on behalf of the Company in any manner. 

Your employment relationship is at-will. Accordingly, you may terminate your employment with the Company at any time and for any reason whatsoever simply by
notifying the Company. Likewise, the Company may terminate your employment at any time, with or without cause or advance notice. 
 It is intended that all
of the benefits and payments under this letter satisfy, to the greatest extent possible, the exemptions from the application of Code Section 409A provided under Treasury Regulations 1.409A 1(b)(4), 1.409A 1(b)(5) and 1.409A 1(b)(9), and this
letter will be construed to the greatest extent possible as consistent with those provisions. If not so exempt, this letter (and any definitions hereunder) will be construed in a manner that complies with Code Section 409A, and incorporates by
reference all required definitions and payment terms. For purposes of Code Section 409A (including, without limitation, for purposes of Treasury Regulation Section 1.409A 2(b)(2)(iii)), your right to receive any installment payments under
this letter (whether severance payments, reimbursements or otherwise) will be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder will at all times be considered a separate and distinct
payment. Notwithstanding any provision to the contrary in this letter, if you are deemed by the Company at the time of your Separation from Service to be a “specified employee” for purposes of Code Section 409A(a)(2)(B)(i), and if any
of the payments upon your Termination of Services set forth herein and/or under any other agreement with the Company are deemed to be “deferred compensation”, then if delayed commencement of any portion of such payments is required to
avoid a prohibited distribution under Code Section 409A(a)(2)(B)(i) and the related adverse taxation under Code Section 409A, the timing of the payments upon your Separation from Service will be delayed as follows: on the earlier to occur
of (i) the date that is six months and one day after the effective date of your Termination of Services, and (ii) the date of the your death (such earlier date, the “Delayed Initial Payment Date”), the Company will (A) pay
to you a lump sum amount equal to the sum of the payments 

 Chas McKhann 

January 21, 2015 
  Page
 5
 
  

 
upon your Separation from Service that you would otherwise have received through the Delayed Initial Payment Date if the commencement of the payments had not been delayed pursuant to this
paragraph, and (B) commence paying the balance of the payments in accordance with the applicable payment schedules set forth above. 
 This letter,
together with your Confidential Information Agreement, forms the complete and exclusive statement of your agreement with the Company concerning the subject matter hereof. The terms in this letter supersede any other representations or agreements
made to you by any party, whether oral or written. The terms of this agreement cannot be changed (except with respect to those changes expressly reserved to the Company’s discretion in this letter) without a written agreement signed by you and
a duly authorized officer of the Company. This agreement is to be governed by the laws of the state of California without reference to conflicts of law principles. In case any provision contained in this agreement shall, for any reason, be held
invalid or unenforceable in any respect, such invalidity or unenforceability shall not affect the other provisions of this agreement, and such provision will be construed and enforced so as to render it valid and enforceable consistent with the
general intent of the parties insofar as possible under applicable law. With respect to the enforcement of this agreement, no waiver of any right hereunder shall be effective unless it is in writing. For purposes of construction of this agreement,
any ambiguity shall not be construed against either party as the drafter. This agreement may be executed in more than one counterpart, and signatures transmitted via facsimile shall be deemed equivalent to originals. As required by law, this offer
is subject to satisfactory proof of your identity and right to work in the United States. 
 If you wish to accept employment at the Company under the terms
described above, please sign and date this letter and the Confidential Information Agreement, and return them to me by January 23, 2015. If you accept our offer, we would like you to start work on February 2, 2015 (“Commencement
Date”). 
 We look forward to your favorable reply and to a productive and enjoyable work relationship. 

Sincerely, 
  

					
	 /s/ Lisa Earnhardt
				
	Lisa Earnhardt				
	Chief Executive Officer				

 Understood and Accepted: 
  

					
	 /s/ Chas McKhann
				 1/22/2015

	Chas McKhann				Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}]]